EUVIMEDEUVIMED entdecken
Vergleichsstudie

The cost‐utility and budget impact analyses of Tirzepatide versus once‐weekly Semaglutide as add‐on therapy to metformin in patients with type 2 diabetes mellitus in China

Sihua Wang iD, Duncong Fan, Qinhong Yao, Xiaojie Sun iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16580 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Sihua Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Haining People's Hospital, Haining City, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Metformin, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Zhejiang Medical Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the long‐term economic implications and potential budgetary consequences for the national health insurance system (NHIS) of tirzepatide versus semaglutide as add‐on therapy to metformin in patients with type 2 diabetes mellitus (T2DM) in China.

Methods

The demographic and clinical efficacy data were derived from the SURPASS‐2 trial. The cost‐utility analysis was performed to estimate the cost‐utility by UK Prospective Diabetes Study Outcomes Model Version 2.2 from the Chinese health care providers' perspective, incorporating costs and quality‐adjusted life years (QALYs). Sensitivity analyses were employed to investigate the presence of uncertainty. The financial implications for the relevant budgetary authority over 5 years were estimated.

Results

In the long‐term treatment simulation, tirzepatide 5 and 10 mg yielded incremental QALYs of 0.05 and 0.09, in comparison with semaglutide 1 mg, respectively. The associated incremental costs for these treatments were $23 563.42 and $47 583.74, respectively. Consequently, the incremental cost‐utility ratios were calculated to be $445 125.24/QALY and $543 829.19/QALY, both of which exceeded the established threshold of $29 599.90/QALY. These base‐case results were validated through robust sensitivity analyses. The budget impact analysis showed that such an expansion would incur an additional budgetary burden of approximately $80 million to $490 million for the NHIS over a simulated 5‐year period.

Conclusion

This dual analysis provides policymakers and payers with a comprehensive basis for decision‐making. Tirzepatide offered substantial long‐term health benefits, but they were not cost‐effective compared with semaglutide 1 mg in T2DM patients inadequately controlled with metformin under China's health care providers' perspective. The entry of tirzepatide 5 mg into the NHIS may increase the financial burden of national medical insurance, but overall health care expenditures are expected to decrease, driven primarily by significantly reduced out‐of‐pocket expenses for patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesMetforminHypoglycemic AgentsHumansCost-Benefit AnalysisChinaQuality-Adjusted Life YearsDrug Therapy, CombinationFemaleMaleMiddle AgedBudgetsAgedDrug Administration ScheduleTirzepatideGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

budget impact analysiscost‐utility analysissemaglutidetirzepatidetype 2 diabetes mellitus

Substanzen

Glucagon-Like PeptidesMetforminHypoglycemic AgentsTirzepatideGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Pharmacy, Haining People's Hospital, Haining City, China.

ORCID-Profile: Sihua Wang, Xiaojie Sun

Förderung

  • Zhejiang Medical Association

Zitieren

APA

Wang, S., Fan, D., Yao, Q., & Sun, X. (2025). The cost‐utility and budget impact analyses of Tirzepatide versus once‐weekly Semaglutide as add‐on therapy to metformin in patients with type 2 diabetes mellitus in China. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16580

Vancouver

Wang S, Fan D, Yao Q, Sun X. The cost‐utility and budget impact analyses of Tirzepatide versus once‐weekly Semaglutide as add‐on therapy to metformin in patients with type 2 diabetes mellitus in China. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16580

BibTeX
@article{Wang2025,
  author = {Wang, Sihua and Fan, Duncong and Yao, Qinhong and Sun, Xiaojie},
  title = {The cost‐utility and budget impact analyses of Tirzepatide versus once‐weekly Semaglutide as add‐on therapy to metformin in patients with type 2 diabetes mellitus in China},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16580}
}
Kostenlos starten →